Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,558 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.
Hazuda DJ, Anthony NJ, Gomez RP, Jolly SM, Wai JS, Zhuang L, Fisher TE, Embrey M, Guare JP Jr, Egbertson MS, Vacca JP, Huff JR, Felock PJ, Witmer MV, Stillmock KA, Danovich R, Grobler J, Miller MD, Espeseth AS, Jin L, Chen IW, Lin JH, Kassahun K, Ellis JD, Wong BK, Xu W, Pearson PG, Schleif WA, Cortese R, Emini E, Summa V, Holloway MK, Young SD. Hazuda DJ, et al. Among authors: lin jh. Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11233-8. doi: 10.1073/pnas.0402357101. Epub 2004 Jul 26. Proc Natl Acad Sci U S A. 2004. PMID: 15277684 Free PMC article.
Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein.
Hochman JH, Yamazaki M, Ohe T, Lin JH. Hochman JH, et al. Among authors: lin jh. Curr Drug Metab. 2002 Jun;3(3):257-73. doi: 10.2174/1389200023337559. Curr Drug Metab. 2002. PMID: 12083320 Review.
Mechanistic studies on metabolic interactions between gemfibrozil and statins.
Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, Baillie TA. Prueksaritanont T, et al. Among authors: lin jh. J Pharmacol Exp Ther. 2002 Jun;301(3):1042-51. doi: 10.1124/jpet.301.3.1042. J Pharmacol Exp Ther. 2002. PMID: 12023536
Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.
Prueksaritanont T, Lin JH, Baillie TA. Prueksaritanont T, et al. Among authors: lin jh. Toxicol Appl Pharmacol. 2006 Dec 1;217(2):143-52. doi: 10.1016/j.taap.2006.08.009. Epub 2006 Sep 1. Toxicol Appl Pharmacol. 2006. PMID: 17055014
In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.
Prueksaritanont T, Kuo Y, Tang C, Li C, Qiu Y, Lu B, Strong-Basalyga K, Richards K, Carr B, Lin JH. Prueksaritanont T, et al. Among authors: lin jh. Drug Metab Dispos. 2006 Sep;34(9):1546-55. doi: 10.1124/dmd.106.009878. Epub 2006 Jun 16. Drug Metab Dispos. 2006. PMID: 16782766
Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
Kumar S, Kwei GY, Poon GK, Iliff SA, Wang Y, Chen Q, Franklin RB, Didolkar V, Wang RW, Yamazaki M, Chiu SH, Lin JH, Pearson PG, Baillie TA. Kumar S, et al. Among authors: lin jh. J Pharmacol Exp Ther. 2003 Mar;304(3):1161-71. doi: 10.1124/jpet.102.045096. J Pharmacol Exp Ther. 2003. PMID: 12604693
1,558 results
Jump to page
Feedback